Opportunities, resources, and techniques for implementing genomics in clinical care

Manolio, Teri A.; Rowley, Robb; Williams, Marc S.; Roden, Dan M.; Ginsburg, Geoffrey S.; Bult, Carol J.; Chisholm, Rex L.; Deverka, Patricia A.; McLeod, Howard L.; Mensah, George A.; Relling, Mary V.; Rodriguez, Laura Lyman; Tamburro, Cecelia P.; Green, Eric D.

doi:10.1016/s0140-6736(19)31140-7

Cited by 60 publications

(47 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the 12 th edition, the authors were Mary V. Relling and Kathleen Giacomini, while the author for the 13 th edition was Dan Roden. One research area of these authors is the effects of rare and common variants on drug response phenotypes and clinical care, as illustrated in [40].…”

Section: Appendix a Evaluation Of The Pharmacogenetic Chaptermentioning

confidence: 99%

A Quantitative and Narrative Evaluation of Goodman and Gilman’s Pharmacological Basis of Therapeutics

et al. 2019

View full text Add to dashboard Cite

Goodman and Gilman’s The Pharmacological Basis of Therapeutics (GGPBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this study were to describe and evaluate the 13th edition of GGPBT on bases including: (1) author characteristics; (2) recency of citations; (3) conflict of interest (CoI) disclosure; (4) expert evaluation of chapters. Contributors’ (N = 115) sex, professional degrees, and presence of undisclosed potential CoI—as reported by the Center for Medicare and Medicaid’s Open Payments (2013–2017)—were examined. The year of publication of citations was extracted relative to Katzung’s Basic and Clinical Pharmacology (KatBCP), and DiPiro’s Pharmacotherapy: A Pathophysiologic Approach (DiPPAPA). Content experts provided thorough chapter reviews. The percent of GGPBT contributors that were female (20.9%) was equivalent to those in KatBCP (17.0%). Citations in GGPBT (11.5 ± 0.2 years) were significantly older than those in KatBCP (10.4 ± 0.2) and DiPPAPA (9.1 ± 0.1, p < 0.0001). Contributors to GGPBT received USD 3 million in undisclosed remuneration (Maximum author = USD 743,718). In contrast, DiPPAPA made CoI information available. Reviewers noted several strengths but also some areas for improvement. GGPBT will continue to be an important component of the biomedical curriculum. Areas of improvement include a more diverse authorship, improved conflict of interest transparency, and a greater inclusion of more recent citations.

show abstract

Section: Appendix a Evaluation Of The Pharmacogenetic Chaptermentioning

confidence: 99%

A Quantitative and Narrative Evaluation of Goodman and Gilman’s Pharmacological Basis of Therapeutics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This allows areas of deletion or duplication to be identified, supplementing the information from sequencing. 13…”

Section: Genetics and Genomicsmentioning

confidence: 99%

Harveian Oration 2019: Prediction and prevention in the genomic era

Burn

2020

Clinical Medicine

View full text Add to dashboard Cite

“…These new tools, together with increasingly sophisticated statistical and computational methods, have enabled researchers to create rich catalogues of human genomic variants 7,8 , to gain an ever-deepening understanding of the functional complexities of the human genome 5 , and to determine the genomic bases of thousands of human diseases 9,10 . In turn, the past decade has brought the initial realization of genomic medicine 11 , as research successes have been converted into powerful tools for use in healthcare, including somatic genome analysis for cancer (enabling development of targeted therapeutic agents) 12 , non-invasive prenatal genetic screening 13 , and genomics-based tests for a growing set of paediatric conditions and rare disorders 14 , among others.…”

mentioning

confidence: 99%